IQVIA Holdings Inc. $IQV Stake Reduced by Gilliland Jeter Wealth Management LLC

Gilliland Jeter Wealth Management LLC cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 65.7% during the 2nd quarter, Holdings Channel.com reports. The fund owned 1,324 shares of the medical research company’s stock after selling 2,541 shares during the quarter. Gilliland Jeter Wealth Management LLC’s holdings in IQVIA were worth $209,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IQV. Pacer Advisors Inc. raised its position in IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock worth $153,681,000 after acquiring an additional 854,732 shares in the last quarter. JPMorgan Chase & Co. increased its stake in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares in the last quarter. Hawk Ridge Capital Management LP purchased a new position in IQVIA in the 1st quarter worth about $77,096,000. Nuveen LLC purchased a new position in IQVIA in the 1st quarter worth about $76,328,000. Finally, Platinum Investment Management Ltd. purchased a new position in IQVIA in the 2nd quarter worth about $61,585,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 1.3%

Shares of IQV stock opened at $203.16 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $237.34. The firm has a market cap of $34.54 billion, a PE ratio of 29.40, a price-to-earnings-growth ratio of 2.20 and a beta of 1.32. The stock has a 50 day moving average of $188.70 and a 200-day moving average of $168.15. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the company earned $2.64 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on IQV shares. Cowen reissued a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Robert W. Baird lifted their target price on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. HSBC raised IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $195.00 to $235.00 in a research note on Thursday. Evercore ISI lifted their target price on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Wednesday. Nineteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $236.45.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.